By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



11095 Flintkote Avenue
Suite D
San Diego  California  92121  U.S.A.
Phone: Fax:



Company News
Ignyta (RXDX) Receives FDA Orphan Drug Designation For Entrectinib For Treatment Of NTRK Fusion-Positive Solid Tumors 7/10/2017 6:38:13 AM
Ignyta (RXDX) Granted Breakthrough Therapy Designation For Entrectinib By U.S. FDA 5/15/2017 6:16:42 AM
The FDA Calls Ignyta (RXDX)'s Tumor Drug Entrectinib A Breakthrough 5/15/2017 6:16:08 AM
Ignyta (RXDX) Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters’ Option To Purchase Additional Shares 5/10/2017 7:38:06 AM
Ignyta (RXDX) Announces Pricing Of Public Offering Of Common Stock 5/4/2017 6:24:54 AM
Ignyta (RXDX) Announces Proposed Public Offering Of Common Stock 5/3/2017 6:09:34 AM
Ignyta (RXDX) Announces First Quarter 2017 Company Highlights And Financial Results 5/2/2017 6:43:00 AM
Ignyta (RXDX) Updates Progress Towards Entrectinib Dual TRK And ROS1 NDA Submissions 4/28/2017 6:34:51 AM
Ignyta (RXDX) To Host Conference Call And Webcast Update On Entrectinib Program And STARTRK-2 On April 27, 2017 4/25/2017 7:26:19 AM
Ignyta (RXDX) Announces Peer-Reviewed Publication Of Activity Of A TRK Inhibitor In A Primary Brain Tumor: Successful Treatment Of Glioneuronal Tumor With Pan-TRK, CNS-Active Inhibitor Entrectinib Published In Precision Oncology 3/30/2017 6:14:32 AM